Clinical Trials Logo

FGFR2 Gene Translocation clinical trials

View clinical trials related to FGFR2 Gene Translocation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04526106 Active, not recruiting - Cholangiocarcinoma Clinical Trials

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Start date: September 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. The study consists of 3 parts: a dose escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3).

NCT ID: NCT04096417 Active, not recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.